BIODEXA PHARMACEUTICALS-ADR (BDRX)
US59564R7089 - ADR
Overall BDRX gets a fundamental rating of 1 out of 10. We evaluated BDRX against 586 industry peers in the Biotechnology industry. BDRX may be in some trouble as it scores bad on both profitability and health. BDRX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
BDRX had negative earnings in the past year.
BDRX had a negative operating cash flow in the past year.
In the past 5 years BDRX always reported negative net income.
BDRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
BDRX has a worse Return On Assets (-67.15%) than 64.79% of its industry peers.
BDRX has a worse Return On Equity (-151.33%) than 66.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.15% | ||
| ROE | -151.33% | ||
| ROIC | N/A |
ROA(3y)-82.67%
ROA(5y)-101.33%
ROE(3y)-148.56%
ROE(5y)-165.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for BDRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BDRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BDRX has been increased compared to 1 year ago.
The debt/assets ratio for BDRX has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -13.61, we must say that BDRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -13.61, BDRX is not doing good in the industry: 82.56% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.06 indicates that BDRX is not too dependend on debt financing.
BDRX has a worse Debt to Equity ratio (0.06) than 61.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.61 |
ROIC/WACCN/A
WACC7.88%
2.3 Liquidity
A Current Ratio of 1.26 indicates that BDRX should not have too much problems paying its short term obligations.
BDRX has a Current ratio of 1.26. This is amonst the worse of the industry: BDRX underperforms 86.15% of its industry peers.
BDRX has a Quick Ratio of 1.26. This is a normal value and indicates that BDRX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.26, BDRX is doing worse than 84.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.26 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 98.55% over the past year.
Looking at the last year, BDRX shows a very negative growth in Revenue. The Revenue has decreased by -45.49% in the last year.
Measured over the past years, BDRX shows a small growth in Revenue. The Revenue has been growing by 3.56% on average per year.
EPS 1Y (TTM)98.55%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q98.8%
Revenue 1Y (TTM)-45.49%
Revenue growth 3Y3.56%
Revenue growth 5YN/A
Revenue growth Q2Q-64.07%
3.2 Future
The Earnings Per Share is expected to grow by 16.56% on average over the next years. This is quite good.
BDRX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.92% yearly.
EPS Next Y99.79%
EPS Next 2Y41.36%
EPS Next 3Y22.67%
EPS Next 5Y16.56%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BDRX. In the last year negative earnings were reported.
Also next year BDRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BDRX's earnings are expected to grow with 22.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.36%
EPS Next 3Y22.67%
5. Dividend
5.1 Amount
BDRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIODEXA PHARMACEUTICALS-ADR
NASDAQ:BDRX (5/17/2024, 7:00:01 PM)
After market: 1.14 -0.05 (-4.2%)1.19
-0.05 (-4.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.22M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.15% | ||
| ROE | -151.33% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)98.55%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y99.79%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-45.49%
Revenue growth 3Y3.56%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y